Outcome of the Innovative Medicines Fund (IMF) Consultation

16 June 2022

Outcome of the Innovative Medicines Fund (IMF) Consultation

You may remember, back in February, SMA UK responded to NICE and NHSEIs' call for engagement on proposals for the Innovative Medicines Fund.

On 6th June, they published their response.

In this document, Zolgensma™, the one off gene-therapy for SMA, is referenced as an example of how successful the mechanisms behind the IMF can be at bringing innovative medicines to the public as quickly and as safely as possible.

We are happy to share with you an extract from the response SMA UK received:

"Thank you for taking the time to engage with the consultation on proposals for the Innovative Medicines Fund (IMF):

Today, NHS England and NHS Improvement (NHSEI), in partnership with the National Institute for Health and Care Excellence (NICE), are publishing our response to consultation and formally opening the IMF.

112 responses to the consultation were received, including from stakeholders in industry (37%), NHS (24%) and patient groups & charities (18%). There was widespread support for the purpose of the Innovative Medicine Fund with 96% of respondents either strongly agreeing, or agreeing, with the purpose of the IMF. Alongside our response to consultation, a new set of IMF Principles set-out the policy approach to the delivery of the Fund, providing clarity on the primary role of the IMF, to enable faster patient access to innovative new treatments

Building on the success of the Cancer Drugs Fund (CDF) that has delivered faster access to cancer treatments for over 80,000 patients, the IMF will support faster access to non-cancer drugs and, alongside the CDF, provide a total of £680 million ringfenced NHS funding for innovative medicines.

Thank you once again for helping to shape the development of the IMF."